We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+47.67%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$62.8M
Cap. Flow
+$27.8M
Cap. Flow %
7.12%
Top 10 Hldgs %
31.01%
Holding
170
New
75
Increased
15
Reduced
22
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.07M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$5.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.14M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.07M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.5M
2
LLY icon
Eli Lilly
LLY
+$11M
3
TGTX icon
TG Therapeutics
TGTX
+$10.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.76M
5
SLNO
Soleno Therapeutics
SLNO
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 36.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
126
PMV Pharmaceuticals
PMVP
$59.7M
$15.8K ﹤0.01%
+11,300
New +$15.6K
APLT
127
CALL
DELISTED
Applied Therapeutics
APLT
$11.5K ﹤0.01%
+19,000
New +$8.95K
AUPH icon
128
PUT
Aurinia Pharmaceuticals
AUPH
$1.9B
$7.74K ﹤0.01%
+700
New +$7.65K
TVTX icon
129
PUT
Travere Therapeutics
TVTX
$5.15B
$7.17K ﹤0.01%
+300
New +$5.64K
JBIO
130
PUT
Jade Biosciences
JBIO
$1.27B
$2.77K ﹤0.01%
+1,046
New +$8.55K
ALT icon
131
PUT
Altimmune
ALT
$583M
– –
-171,400
Closed -$663K
AMGN icon
132
Amgen
AMGN
$207B
– –
-52,100
Closed -$14.5M
AMGN icon
133
PUT
Amgen
AMGN
$207B
– –
-62,100
Closed -$17.3M
ARGX icon
134
argenx
ARGX
$52.5B
– –
-5,974
Closed -$3.29M
ARVN icon
135
Arvinas
ARVN
$589M
– –
-96,455
Closed -$710K
BHVN icon
136
CALL
Biohaven
BHVN
$2.04B
– –
-100,000
Closed -$1.41M
BMEA icon
137
CALL
Biomea Fusion
BMEA
$88.2M
– –
-568,900
Closed -$1.02M
CAPR icon
138
PUT
Capricor Therapeutics
CAPR
$251M
– –
-106,600
Closed -$1.06M
COGT icon
139
PUT
Cogent Biosciences
COGT
$7.28B
– –
-201,400
Closed -$1.45M
CRDF icon
140
CALL
Cardiff Oncology
CRDF
$73.1M
– –
-208,100
Closed -$656K
ELDN icon
141
Eledon Pharmaceuticals
ELDN
$268M
– –
-64,613
Closed -$175K
ELEV
142
DELISTED
Elevation Oncology
ELEV
– –
-362,935
Closed -$133K
ETNB
143
DELISTED
89bio
ETNB
– –
-98,382
Closed -$966K
GILD icon
144
Gilead Sciences
GILD
$163B
– –
-30,000
Closed -$3.33M
ITOS
145
DELISTED
iTeos Therapeutics
ITOS
– –
-206,200
Closed -$2.06M
LLY icon
146
CALL
Eli Lilly
LLY
$1T
– –
-10,000
Closed -$7.8M
LLY icon
147
Eli Lilly
LLY
$1T
– –
-14,816
Closed -$11M
MLTX icon
148
PUT
MoonLake Immunotherapeutics
MLTX
$1.48B
– –
-41,300
Closed -$1.95M
MRK icon
149
Merck
MRK
$318B
– –
-20,000
Closed -$1.58M
NKTR icon
150
CALL
Nektar Therapeutics
NKTR
$2.44B
– –
-47,474
Closed -$85.9K
3 4 5
6
7

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Diadema Partners held 170 positions worth $391M, up 19% from $328M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Diadema Partners deployed $27.8M of net new capital in Q3 2025, opening 75 new positions and adding to 15 existing holdings. Its largest new stake was Bristol-Myers Squibb: 130,000 shares worth $5.86M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 49% a quarter earlier.

On the sell side, the largest reduction was TG Therapeutics, an estimated $10.2M trimmed.

  • Diadema Partners's largest Q3 2025 buy was Bristol-Myers Squibb: 130,000 shares worth $5.86M.
  • Diadema Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $13.9M increase.
  • Diadema Partners's biggest Q3 2025 reduction was TG Therapeutics, cutting an estimated $10.2M.
  • Diadema Partners fully exited Amgen in Q3 2025, selling an estimated $14.5M.
  • Diadema Partners's ten largest holdings make up 31% of its $391M portfolio in Q3 2025.
  • Diadema Partners opened 75 new positions and closed 40 in Q3 2025.
  • Diadema Partners's portfolio value rose 19% quarter-over-quarter to $391M.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.